An agreement to this effect was signed at the ATOMEXPO 2024 International Forum.
A Memorandum of understanding on nuclear medicine cooperation was signed between the Rosatom State Corporation and the Ministry of Health of the Republic of Serbia on March 25, 2024 at the ATOMEXPO International Forum.
The document was signed by ROSATOM’s Director General Alexey Likhachev and Serbian Minister of Health Dr Danica Grujičić.
The parties agreed to implement joint projects on the use of non-power nuclear technologies in healthcare, with a focus on developing nuclear medicine. They plan to make a special emphasis on engagement in matters of diagnostics and treatment of cancer using civilian nuclear technologies. The parties intend to exchange information and expertise in nuclear medicine and healthcare applications of radiation technologies, cooperate in further professional development of healthcare workers, and jointly develop the infrastructure required for using radiation technologies in cancer diagnostics and treatment.
Rosatom Health Technologies, the business unit accumulating ROSATOM’s healthcare expertise, will be managing the development of the partnership.
“ROSATOM’s approach to the implementation of its healthcare goals is as comprehensive as possible. This line of work includes a complex of isotopes and the production of radiopharmaceuticals, high-tech medical equipment, medical devices and food products, as well as construction of our own medical facilities. We are happy to have opportunities to develop innovative civilian nuclear technologies together with friendly foreign states, for the sake of better health and life quality of our citizens,” commented Alexey Likhachev.
“Given ROSATOM’s considerable expertise and competencies in nuclear medicine projects, I am confident that our joint work will drive significant progress in the diagnostics and treatment of socially relevant diseases, including cancer. Our joint work is aimed at our countries’ top priority of ensuring access to cutting-edge health maintenance and improvement technologies to our doctors and patients,” highlighted Dr Danica Grujičić.
For reference:
Rosatom Health Technologies accumulates healthcare expertise of ROSATOM. The company integrated a number of ROSATOM’s business units and institutes for comprehensive development of medical technologies in Russia and abroad. The healthcare arm develops in four key directions: comprehensive medical solutions, isotopic products manufacturing and supply (to 50 countries), diagnostic and therapeutic equipment, and ionizing radiation solutions.
The ATOMEXPO International Forum, held since 2009, is one of the main events of the global atomic industry. It is the largest exhibition and business platform for discussing the current state of the nuclear industry and setting trends of future development. The exhibition is a space where leading companies of the global nuclear industry and related industries share their technologies and competencies. To demonstrate ROSATOMS’s commitment to the climate agenda, the carbon footprint of the 13th ATOMEXPO 2024 International Forum will be offset based on special certificates.